Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CHILI

Financiado

Cerrado

A Community based HPV screening implementation in Low Income countries

Cervical cancer is the 4th most common cancer in women worldwide, with up to 85% of the burden in resource-restricted countries. Early detection of precancer has shown to be successful in reducing cancer incidence and mortality. H... ver más

31/08/2026

UGent

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-15

SC1-BHC-17-2020: Global Alliance for Chronic Disease...

I+D

Cerrada hace 4 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

UGent

678.54K€ | Lider

UNL

54.14K€ | Participante

UNIVERSIDADE EDUARDO MONDLAN...

NATIONAL INSTITUTE FOR PUBLI...

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SELFPOCNAD SelfPOCNAD Development of a Point of Care Detection Device... 2M€ Cerrado

MIMICS MicroRNA Isoforms for Molecular Interception of Cervical can... 150K€ Cerrado

HPV OncoPredict A Groundbreaking Stand Alone Diagnostic Kit to Predict Human... 3M€ Cerrado

PRESCRIP-TEC Prevention and Screening Innovation Project Towards Eliminat... 3M€ Cerrado

VALPAS VALidation of human PApilloma virus assays on Self collected... 71K€ Cerrado

HoloCyt A rapid low cost cervical cancer screening platform 71K€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2021-02-15
Fecha Fin: 2026-08-31

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cervical cancer is the 4th most common cancer in women worldwide, with up to 85% of the burden in resource-restricted countries. Early detection of precancer has shown to be successful in reducing cancer incidence and mortality. However, a global implementation of this approach is hampered by culture and resource differences between countries. We propose to evaluate the acceptability, feasibility and cost-effectiveness of the ELEVATE cervical cancer screening tool in low-income countries (LIC). The tool is a portable, battery-powered device compatible with self-sampling and comprises an HPV DNA test as well as a proteomic biomarkers detection sensor and will be offered to women in Ethiopia, Cambodia, Mozambique and Uganda. This multidisciplinary consortium, led by Ghent University (Belgium), brings together social scientists, health economists and biosensor experts from Europe and the selected countries with industry partners. The approach is three-fold: social science investigations will be conducted to understand current screening practices and to define a tailored strategy, including the ELEVATE tool, embedded in the current health system. Secondly, engineers will validate the self-testing device and will adapt it to reduce the unit price and to enable large-scale manufacturing at an affordable cost. Finally, public health specialists and health economists will evaluate the implementation of the new screening tool to assess its appropriateness and cost-effectiveness. For the latter objective, an intervention will be implemented: in the first arm, the different steps of current cervical cancer screening practices will be optimized (awareness, pre-and post-counseling and referral). In the second arm, the same strategy will be applied in combination with the new point-of-care screening device. Integral part of CHILI is to maximize the use of the new screening tool in low-resource settings in collaboration with national stakeholders and health care providers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores